OpGen, Inc. OPGN
23.91 USD 0.00 (+0.00%)
Mar 19, 2026, 9:30 AM EDT
23.91 Day range 23.91
1.75 52-week range 38.40
- YTD
- +50.38%
- 1 year
- +386.97%
- Market cap
- 16.79M
- Revenue (ttm)
- 1.96M
- EPS (ttm)
- -40.32
- Shares out
- 8.36M
- Forward P/E
- -6.93
- YTD return
- +50.38%
- 1-year return
- +386.97%
- Volume
- 1.28K
- Avg volume
- 17.08K
- Open
- 23.91
- Previous close
- 23.91
- Day's range
- 23.91 – 23.91
- 52-week range
- 1.75 – 38.40
- Beta
- -0.66
- Analysts
- Hold
- Earnings date
- Apr 3, 2024
2Y -1.3230 (-80.18%)
Key statistics
- Enterprise value
- 31.42M
- PEG ratio
- 0.00
- Price / sales
- 8.55
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -96.20%
- Free cash flow
- -2.87M
- Total cash
- 168.11K
- Total debt
- 13.20M
- Return on equity
- 0.00%
- Short % of float
- 1.79%
- 50-day average
- 2.46
- 200-day average
- 3.84
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 3, 2024
Expected Apr 3, 2024. Consensus EPS estimate 0.00.
Financials — quick view
OPGN Revenue — quarterly 28.00K
OPGN Net income — quarterly -1.58M
OPGN EPS — quarterly -1.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2024 | Sep 1, 2024 | 0.00 | 1.35 | — | — |
| Aug 19, 2024 | Jun 1, 2024 | 0.00 | -1.18 | — | — |
| Jul 8, 2024 | Mar 1, 2024 | 0.00 | 0.21 | — | — |
| Apr 3, 2024 | Dec 1, 2023 | -0.13 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -4.30 | -4.60 | -0.30 | -6.98% |
| Aug 10, 2023 | Jun 1, 2023 | -7.10 | -9.30 | -2.20 | -30.99% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jul 19, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 20, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About OpGen, Inc.
OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. OpGen, Inc. was incorporated in 2001 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- opgen.com
News
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Why Lands' End Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Stocks That Hit 52-Week Lows On Monday 
Stocks That Hit 52-Week Lows On Friday - Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Stocks That Hit 52-Week Lows On Thursday - Earnings Scheduled For August 10, 2023
Your note
Sign in to keep a note on OPGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEN-TZVI AVRAHAM | Director | Stock Award(Grant) | Apr 10, 2024 | 100,000 |
| CROVETTO MARIO PIETRO | Director | Stock Award(Grant) | Jun 6, 2023 | 3,000 |
| ELSEY RAYMOND DON | Director | Stock Award(Grant) | Jun 6, 2023 | 3,075 |
| FERNANDES PRABHAVATHI | Director | Stock Award(Grant) | Jun 6, 2023 | 3,000 |
| LAZAR DAVID ELLIOT | Chief Executive Officer | Stock Award(Grant) | Apr 10, 2024 | 100,000 |
| MCMURDO MATTHEW CHARLES | Director | Stock Award(Grant) | Apr 10, 2024 | 100,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 7.04% | 626,175 | 510.27K | Jun 29, 2023 |
| Vanguard Group Inc | 0.41% | 36,701 | 29.91K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.20% | 18,090 | 14.74K | Jun 29, 2023 |
| Blackrock Inc. | 0.18% | 16,038 | 13.07K | Jun 29, 2023 |
| Arete Wealth Advisors, LLC | 0.17% | 15,000 | 12.22K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.09% | 8,018 | 6.53K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.41% | 36,701 | 29.91K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.11% | 9,677 | 7.27K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.03% | 2,732 | 2.05K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.03% | 3,032 | 2.28K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,305 | 980 | May 30, 2023 |